Home › Down Syndrome › NCT07643896
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
ADVANCE Study: Assay Development and Validation for Pre-Natal and Obstetric Conditions
Who can join
All ages · Women
Full eligibility criteria
Inclusion Criteria: * pregnant individuals between 10 and 20 weeks of gestation * singleton gestation Exclusion Criteria: \- active cancer
About the study
The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.
Sponsor: BillionToOne Inc. · Participants: 1,000 · Started: Jan 10, 2026
Contact the study team
- Shannon O'Rourke Senior Research Manager, MS, CGC · Phone: 650-460-2551
Official record on ClinicalTrials.gov — NCT07643896
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.